ReviewFundamental research2025
The interaction network between group 3 innate lymphoid cells and other cells.
Review in Fundamental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Innate immunity: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- RORγtNature communications · 2026Article
- Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer.Frontiers in immunology · 2026Review
- Spatial mapping of innate lymphoid cells in human lymphoid tissues and lymphoma at single-cell resolution.Nature communications · 2025Article
- p38α-eIF6-Nsun2 axis promotes ILC3's rapid response to protect host from intestinal inflammation.The Journal of experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group 3 innate lymphoid cells (ILC3s) have emerged as significant regulators of tissue homeostasis, immunity and inflammation through various effector molecules in response to signals within the tissue microenvironment. Multiple signals derived from the tissue microenvironment have been illustrated in recent years, which could either activate or suppress the activity of ILC3s. ILC3s, in turn, could also influence many other cells through their effector molecules, such as interleukin (IL)-22, IL-17 and lymphotoxins, indicating that ILC3s act as an important hub in the complex network of cell interactions. In this review, we discuss our current appreciation of the functional crosstalk between ILC3s and myeloid cells, T and B cells, epithelial cells or other types of cells, thus highlighting the emerging importance of communication between these cells for the prevention or induction of relevant diseases and providing insights for future directions of investigation and therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.